Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists hunt for a yardstick to measure rare nerve damage

NCT ID NCT07651540

Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Saint Etienne Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study looks at 70 adults with sensory neuronopathy, a rare nerve condition that causes balance and coordination problems. Researchers will test several clinical scales over 12 months to see which one best tracks how the disease changes over time. The goal is to find a reliable tool for monitoring the condition and assessing future treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could identify a reliable way to measure disease progression in sensory neuronopathy, helping doctors better track the condition and evaluate treatments.
What could go wrong
This is an observational study, not a treatment trial. It may not find a clear winner among the scales, and results may not apply to all patients with sensory neuronopathy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient affiliated with or beneficiary of a social security system * Patient having received appropriate study information * Adult patient ≥18 years old, male or female * Patient diagnosed with probable SN according to Camdessanché et al. diagnostic criteria * SN with one of the following etiologies: Paraneoplastic SN with anti-Hu or anti-CV2/CRMP5 antibodies SN associated with Sjögren's syndrome, systemic lupus erythematosus, or primary biliary cholangitis Platinum-salt-induced SN SN caused by CANVAS syndrome Exclusion Criteria: * Patient unable to understand or read French * Patient refusal to participate * Patient known to have another neuropathy phenotype and/or etiology that could significantly influence clinical scales and electrophysiological parameters, including: * Diabetes mellitus * Significant alcohol consumption * Severe chronic kidney disease (GFR \<30 ml/min) * Vitamin B12 and/or vitamin E deficiency * Vitamin B6 excess * Chemotherapy other than platinum salts * HIV infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Paraneoplastic sensory neuronopathy with anti-hu antibodies are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chemotherapy-induced neuropathy paraneoplastic sensory ganglionopathy sensory ganglionopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sensory neuronopathy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    19 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHU St Etienne

    NOT_YET_RECRUITING

    Saint-Etienne, France

  • Chu D Angers

    NOT_YET_RECRUITING

    Angers, France

  • Chu de Clermont Ferrand

    NOT_YET_RECRUITING

    Clermont-Ferrand, France

  • Chu de Grenoble

    NOT_YET_RECRUITING

    Grenoble, France

  • Chu de La Reunion

    NOT_YET_RECRUITING

    Saint-Pierre, France

  • Chu de Lille

    NOT_YET_RECRUITING

    Lille, France

  • Chu de Limoges

    NOT_YET_RECRUITING

    Limoges, France

  • Chu de Nancy

    NOT_YET_RECRUITING

    Nancy, France

  • Chu de Nantes

    NOT_YET_RECRUITING

    Nantes, France

  • Chu de Nice

    NOT_YET_RECRUITING

    Nice, France

  • Chu de Saint-Etienne

    RECRUITING

    Saint-Etienne, 42055, France

  • Chu de Toulouse

    NOT_YET_RECRUITING

    Toulouse, France

  • Chuv Centre Hospitalier Vaudois

    NOT_YET_RECRUITING

    Lausanne, Switzerland

  • Hopital de Sion

    NOT_YET_RECRUITING

    Sion, Switzerland

  • Hopital, Bicetre

    NOT_YET_RECRUITING

    Paris, France

  • Hopitaux Universitaire de Geneve

    NOT_YET_RECRUITING

    Geneva, Switzerland

  • Hopitaux Universitaire de Marseille

    NOT_YET_RECRUITING

    Marseille, France

  • Hopitaux Universitaire de Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, France

  • Hospices Civils de Lyon

    NOT_YET_RECRUITING

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.